Reckitt Benckiser: UBS maintains 'buy' rating

(CercleFinance.com) - UBS has reinstates its 'buy' rating on Reckitt Benckiser shares, maintaining its target price at 8,300p, which represents upside potential of 29% for the UK health and personal care products group's shares.


"RB OTC will be impacted by lower instances of cough & cold and tough comps in 1H21E," it warns, however.

Even so, the broker sees two distinct halves of 2021 for this business, believing that "improved fundamentals will pave the way for recovery from 2H21E onwards".


Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.